{"id":"4372fe10-a5db-596a-b55b-a20e532424fa","stable_key":"d71929ae-ed38-52ed-b512-f92b9b148b71:stat3-kd-gpx4-mrna","predicate":"has_contextual_experimental_result","statement":"STAT3 siRNA reduced GPX4 mRNA in the reported gallbladder cancer-cell experiments.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"ee107597-e9de-5363-b531-fe720fc4f1c0","mechanism_event_label":"stat3-kd-gpx4-mrna","subject":{"id":"814c9a36-9034-53b8-b0f3-e5a577bc8f56","slug":"human-stat3-knockdown-gbc","display_name":"STAT3 siRNA knockdown in human gallbladder cancer cells","entity_type_key":"protein_state"},"object":{"id":"8010f092-9f24-5fb1-8f83-ff45f316512c","slug":"human-gpx4-mrna-abundance","display_name":"GPX4 mRNA abundance in human cells","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"ee107597-e9de-5363-b531-fe720fc4f1c0","stable_key":"d71929ae-ed38-52ed-b512-f92b9b148b71:stat3-kd-gpx4-mrna","event_type":"experimental_result","label":"stat3-kd-gpx4-mrna","description":"STAT3 siRNA reduced GPX4 mRNA in the reported gallbladder cancer-cell experiments.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"814c9a36-9034-53b8-b0f3-e5a577bc8f56","slug":"human-stat3-knockdown-gbc","display_name":"STAT3 siRNA knockdown in human gallbladder cancer cells","entity_type_key":"protein_state"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"8010f092-9f24-5fb1-8f83-ff45f316512c","slug":"human-gpx4-mrna-abundance","display_name":"GPX4 mRNA abundance in human cells","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"dc129d3d-aaa0-5511-9a60-3e3880b0eb0f","slug":"stat3","display_name":"STAT3","entity_type_key":"protein"},"role":"silenced transcription factor","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"e9bb13ee-f238-51e6-9101-78ddfd11465c","slug":"gpx4","display_name":"GPX4","entity_type_key":"protein"},"role":"transcript gene","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"experimental_model","value_text":"Human NOZ and GBC-SD gallbladder cancer cells","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"siSTAT3 versus control; reciprocal STAT3 overexpression increased mRNA/protein in the same reported figure group. Transfection duration not independently resolved here.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Human cancer-cell experiments; no clinical or dietary inference. Solasonine exposure is not equivalent to APT2 depletion, ML349, or sulforaphane. Mutant rescue does not by itself establish selectivity or normal baseline mutant function. Figure 5C calls this APT2 activity, but Methods 2.17 describes an anti-LYPLA2 ELISA with mass-concentration standards and an HRP/TMB readout from cell supernatants. No direct APT2 substrate-turnover assay is described there. The result is retained as an author-labelled activity proxy, not established catalytic inhibition. This methodological qualification does not invalidate the separately reported binding or cellular observations.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_locator","value_text":"Figure 3A-D and Supplementary Figure S3A-B; Results 3.3.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"https://doi.org/10.1002/ptr.70245","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"5d1dec3a-5158-5a80-9a70-5400267420b5","evidence_kind":"source_excerpt","locator":"Lines 141-147","start_line":141,"end_line":147,"excerpt":"STAT3 siRNA reduced GPX4 mRNA in the reported gallbladder cancer-cell experiments.\nprimary_references: https://doi.org/10.1002/ptr.70245\nprimary_locator: Figure 3A-D and Supplementary Figure S3A-B; Results 3.3.\norganism: Human\nexperimental_model: Human NOZ and GBC-SD gallbladder cancer cells\nexposure: siSTAT3 versus control; reciprocal STAT3 overexpression increased mRNA/protein in the same reported figure group. Transfection duration not independently resolved here.\nlimitations: Human cancer-cell experiments; no clinical or dietary inference. Solasonine exposure is not equivalent to APT2 depletion, ML349, or sulforaphane. Mutant rescue does not by itself establish selectivity or normal baseline mutant function. Figure 5C calls this APT2 activity, but Methods 2.17 describes an anti-LYPLA2 ELISA with mass-concentration standards and an HRP/TMB readout from cell supernatants. No direct APT2 substrate-turnover assay is described there. The result is retained as an author-labelled activity proxy, not established catalytic inhibition. This methodological qualification does not invalidate the separately reported binding or cellular observations.","model_system":"Human NOZ and GBC-SD gallbladder cancer cells","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Curator paraphrase, not a publisher quotation. Methodological inference is explicitly identified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"15a55d0b-bd44-54e4-9080-5526d1a9744d","stable_key":"import-d71929ae-ed38-52ed-b512-f92b9b148b71","title":"APT2, STAT3 and GPX4: opposing branches and assay qualification","document_type":"imported_text","citation_label":"Primary observations: 10.1038/s41467-025-56344-5 and 10.1002/ptr.70245; selected full-text review 2026-09-20.","file_path":"","sha256":"6fd94803c436074e7b2c15e9a817e751c3d95f6fe1d35a4af63ab641a8f33fe0","revision_id":"d59d5472-18d2-5feb-bc2e-529ceda00956","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}